| ADARx Pharmaceuticals | Rare disease / Hereditary angioedema / RNA interference | Onvuzosiran (siRNA for prevention of hereditary angioedema attacks) | Phase 3 | 24 Sep 2026 | $17.00 | $513.2M | ~$1.81B | +13.8% | +4.6% |
| Electra Therapeutics | Immunology / Hyperinflammatory disease (secondary haemophagocytic lymphohistiocytosis) | Ipsoprubart (ELA026) — in a global registrational programme in secondary HLH, with a separate Phase 1 in relapsed/refractory T-cell and NK-cell malignancies | Phase 2/3 | 17 Sep 2026 | $15.00 | $350.0M | ~$941.5M | -11.7% | -39.7% |
| Vogenx | Metabolic disease / Endocrinology (post-bariatric hypoglycemia, gastroparesis, GIP-dependent Cushing’s syndrome) | Mizagliflozin (oral selective SGLT1 inhibitor; lead indication post-bariatric hypoglycemia, with gastroparesis and GIP-dependent Cushing’s syndrome behind it) | Phase 2 | 11 Aug 2026 | $13.00 | $81.3M | ~$180.9M | +8.4% | +35.1% |
| Latigo Biotherapeutics | Pain / Non-opioid analgesia (acute and chronic pain) | LTG-001 (oral Nav1.8 inhibitor; moderate-to-severe acute pain, positive 343-patient abdominoplasty Phase 2b published in NEJM) | Phase 3-ready | 06 Aug 2026 | $18.00 | $345.6M | ~$1.3B | +1.0% | -11.1% |
| BlossomHill Therapeutics | Oncology / Targeted small molecules (EGFR-mutant NSCLC, R/R AML) | BH-30643 (macrocyclic, non-covalent, brain-active, mutant-selective OMNI-EGFR inhibitor; EGFR- and HER2-mutated NSCLC, initial focus on the C797S resistance population after 3rd-generation EGFR TKI). Second clinical asset BH-30236, a macrocyclic CLK inhibitor in R/R AML and higher-risk MDS | Phase 1/2 | 06 Aug 2026 | $16.00 | $168.3M | ~$490.3M | 0.0% | +9.3% |
| Braveheart Bio | Cardiovascular / Genetic cardiomyopathy | BHB-1893 (oral cardiac myosin inhibitor licensed from Hengrui; obstructive hypertrophic cardiomyopathy) | Phase 3-ready | 05 Aug 2026 | $18.00 | $382.5M | ~$1.3B | +66.0% | +11.2% |
| Attovia Therapeutics | Immunology / Dermatology (chronic pruritus, atopic dermatitis) | ATTO-1310 (half-life-extended anti-IL-31 ATTOBODY biparatopic nanobody; chronic pruritus and high-itch atopic dermatitis) | Phase 1b | 04 Aug 2026 | $17.00 | $289.0M | ~$767M | +28.8% | -4.6% |
| Apnimed | Sleep medicine / Sleep-related breathing disorders | AD109 / Oxnimbi (oral aroxybutynin-atomoxetine; obstructive sleep apnea, PDUFA 28 Feb 2027) | Phase 3 complete | 30 Jul 2026 | $16.00 | $192.0M | ~$680M | +56.3% | +15.8% |
| Scribe Therapeutics | Cardiovascular / Gene editing (epigenetic silencing) | PCSK9- and Lp(a)-lowering epigenetic silencing candidate (lipid-lowering genetic medicine) | Phase 1 | 24 Jul 2026 | $15.00 | $128.7M | ~$440M | +44.3% | +41.1% |
| Kardigan | Cardiovascular / Precision medicines | danicamtiv, ataciguat and tonlamarsen (three late-stage cardiovascular programs) | Phase 2b/3 | 18 Jun 2026 | $16.00 | $400.0M | ~$1.4B | +37.5% | -8.3% |
| Parabilis Medicines | Oncology / Peptide therapeutics / Hard-to-drug targets | zolucatetide (clinical-stage Helicon peptide; desmoid tumors and other solid tumors) | Phase 1/2 | 10 Jun 2026 | $20.00 | $670.0M | ~$2.3B | +58.0% | +37.4% |
| Odyssey Therapeutics | Autoimmune / Inflammation | OD-001 (oral RIPK2 inhibitor; ulcerative colitis) | Phase 2 | 07 May 2026 | $18.00 | $279.0M | ~$900M | -8.8% | +5.6% |
| Hemab Therapeutics | Rare bleeding disorders | sutacimig / HMB-001 (bispecific antibody; Glanzmann thrombasthenia) | Phase 3-ready | 30 Apr 2026 | $18.00 | $346.7M | ~$841M | +88.9% | +75.7% |
| Seaport Therapeutics | Neuropsychiatry | GlyphAllo (oral neuroactive steroid; major depressive disorder) | Phase 2b | 30 Apr 2026 | $18.00 | $254.9M | ~$912M | +10.2% | +0.8% |
| Avalyn Pharma | Rare lung disease | AP01 (inhaled pirfenidone; idiopathic pulmonary fibrosis) | Phase 2/3 | 29 Apr 2026 | $18.00 | $345.0M | ~$813M | +63.8% | +43.1% |
| Kailera Therapeutics | Obesity / Metabolic disease | ribupatide (GLP-1/GIP dual agonist; obesity) | Phase 3 | 16 Apr 2026 | $16.00 | $625.0M | ~$2.0B | +62.5% | -27.4% |
| Alamar Biosciences | Proteomics / Diagnostics | NULISA / ARGO HT System (ultrasensitive proteomics platform) | Commercial | 16 Apr 2026 | $17.00 | $219.9M | ~$1.53B | +33.0% | +48.6% |
| Generate Biomedicines | Inflammation / Immunology / Oncology | GB-0895 (half-life-extended anti-TSLP; severe asthma) | Phase 3 | 26 Feb 2026 | $16.00 | $400M | ~$2.2B | -21.0% | -10.4% |
| SpyGlass Pharma | Ophthalmology | BIM-IOL System (bimatoprost drug-pad IOL; OAG/OHT) | Phase 3 | 05 Feb 2026 | $16.00 | $172.5M | ~$842M | +65.0% | +55.8% |
| Agomab Therapeutics | Inflammation / Fibrosis | AGMB-129 / ontunisertib (oral ALK5 inhibitor; fibrostenosing Crohn's) | Phase 2a | 05 Feb 2026 | $16.00 | $200M | ~$780M | -8.4% | -43.3% |
| Eikon Therapeutics | Oncology | EIK1001 (TLR7/8 agonist; advanced melanoma) | Phase 2/3 | 04 Feb 2026 | $18.00 | $381M | ~$972M | -16.7% | -58.5% |
| Veradermics | Aesthetic dermatology | VDPHL01 (extended-release oral minoxidil; androgenetic alopecia) | Phase 3 | 03 Feb 2026 | $17.00 | $294.8M | ~$596M | +122.1% | +670.0% |
| Aktis Oncology | Oncology | 225Ac-AKY-1189 (Nectin-4-targeting radioligand; solid tumors) | Phase 1b | 08 Jan 2026 | $18.00 | $365.4M | ~$945M | +24.4% | +0.8% |
